Trading in Azitra Inc. (AZTR) was halted on Nasdaq on October 13, 2026, because of an unspecified “regulatory concern”. This halt occurred despite the company’s recent announcement on August 21, 2026, that it had regained full compliance with NYSE American continued listing standards.

Investors currently lack specific details regarding the reason for the halt. The sudden interruption in trading, occurring shortly after Azitra’s resolution of previous compliance issues, leaves the market without immediate clarity on the nature of the current concern or its potential implications for the company's listing status.

What the records show

Official Nasdaq documentation from NasdaqTrader.com reported a trading halt for Azitra Inc. (AZTR) effective October 13, 2026. The stated cause for this halt was an “H11 Regulatory Concern,” which designates a halt for a regulatory concern in conjunction with another exchange or market. Azitra, a clinical-stage biopharmaceutical company focused on dermatology therapies, registers its common stock on the NYSE American exchange.

Azitra’s SEC filings confirm its primary listing venue. The Nasdaq halt took place even though the company had publicly announced on August 21, 2026, that it received written notification from NYSE American LLC confirming its full compliance with all continued listing standards. This notification, dated August 19, 2026, came in a letter from NYSE Regulation. The letter specifically stated that Azitra had resolved previously disclosed deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. As a result, the “below compliance” (“.BC”) indicator was to be removed from Azitra’s trading symbol, and the company would be taken off NYSE American’s list of noncompliant issuers.

However, the August 19, 2026, letter from NYSE Regulation also included a critical stipulation. Under Section 1009(h) of the NYSE American Company Guide, if Azitra were to fall below any continued listing standards again within 12 months of the letter’s date, NYSE American would “examine the relationship between the two incidents of noncompliance and re-evaluate the Company's method of financial recovery from the first incident”. Depending on the specific circumstances, NYSE American could then “truncat[e] the compliance procedures” or “immediately initiat[e] delisting proceedings”. This 12-month monitoring period extends until August 19, 2027. The trading halt on October 13, 2026, occurred within this probationary timeframe.

The timeline

Azitra’s listing status faced challenges beginning in late 2025. On October 1, 2025, NYSE American issued a notice to Azitra indicating non-compliance with Section 1003(a)(ii) of the Company Guide. This section requires a minimum stockholders' equity of $4.0 million for companies that have reported losses from continuing operations or net losses in three of the four most recent fiscal years. Azitra responded by submitting a plan to regain compliance on October 31, 2025, which NYSE American subsequently accepted on December 16, 2025.

A second notice of non-compliance arrived on March 13, 2026, this time pertaining to Section 1003(a)(iii) of the NYSE American Company Guide. This section mandates that a listed company must have stockholders' equity of $6 million or more if it has reported losses from continuing operations or net losses in its five most recent fiscal years. The company received a deadline of April 1, 2027, to regain compliance with both Section 1003(a)(ii) and Section 1003(a)(iii).

On August 21, 2026, Azitra made a public announcement that it had regained compliance. The company cited a letter dated August 19, 2026, from NYSE Regulation as confirmation. This letter informed Azitra that it had successfully resolved the prior deficiencies under Section 1003(a)(ii) and Section 1003(a)(iii) of the NYSE American Company Guide. The public .BC indicator was to be removed from Azitra’s trading symbol, and the company would no longer be listed as noncompliant on NYSE American’s website.

Before the October 13, 2026, trading halt, Azitra’s most recent press release was dated October 1, 2026. This release announced the advancement of its ATR-04 Phase 1/2 Clinical Trial to Cohort 2. Then, on October 13, 2026, trading in Azitra Inc. was halted on Nasdaq due to a regulatory concern.

What changed and for whom

The August 21, 2026, announcement marked a change in Azitra’s official listing status with NYSE American. The company transitioned from a state of non-compliance to one of full compliance with the exchange’s continued listing standards. This resolution meant the removal of the .BC indicator from its trading symbol and its removal from NYSE American’s public list of noncompliant issuers.

Despite regaining compliance, Azitra remained under the monitoring procedures of NYSE Regulation. The August 19, 2026, letter included a specific provision under Section 1009(h) of the NYSE American Company Guide. This section outlines that if Azitra again falls below any continued listing standards within 12 months, NYSE American would examine the connection between the two incidents of noncompliance. This provision allows NYSE American to re-evaluate the company's financial recovery method from the first incident and, depending on the circumstances, potentially shorten normal compliance procedures or immediately begin delisting proceedings. For investors, this meant any new compliance issue within the 12-month period, extending to August 19, 2027, could lead to a more immediate or stringent response from the exchange. The trading halt on October 13, 2026, falls within this period of enhanced scrutiny.

What the subject has said publicly

Francisco Salva, the Chief Executive Officer of Azitra, issued a statement on August 21, 2026, following the notification of compliance. He stated, “We are pleased to have resolved this matter and regained full compliance with the NYSE American continued listing standards”. Salva also communicated the company’s focus on advancing its pipeline. This pipeline includes the ATR-COSF and ATR-04 programs. Azitra describes ATR-04 as an investigational live biotherapeutic for EGFR inhibitor-associated rash, which has received Fast Track designation from the FDA.

The company’s most recent press release prior to the October 13, 2026, trading halt was distributed on October 1, 2026. That release announced that Azitra had advanced its ATR-04 Phase 1/2 Clinical Trial to Cohort 2.

As of the time of this report, Azitra had not publicly released a statement addressing the specific “regulatory concern” that prompted the October 13, 2026, trading halt on Nasdaq.

What we could not confirm

PrimaryBrief could not confirm the exact nature of the “regulatory concern” that led to the Nasdaq trading halt for Azitra Inc. on October 13, 2026. It remains unconfirmed whether this concern represents a new issue for the company or a recurrence of previous compliance challenges. We also could not confirm if the trading halt is connected to the 12-month monitoring period stipulated by NYSE American under Section 1009(h) of its Company Guide, which began on August 19, 2026. Azitra has not publicly commented on the specifics of the halt.